NIDA supports epidemiology, policy investigation and community overall health outcomes research relevant to cannabis use, including the Monitoring the longer term survey and a medicinal cannabis use registry.In 2024, the U.S. Drug Enforcement Administration (DEA) indicated they intend to reclassify cannabis as a Program III drug. This rescheduling